Search results for "phosphodiesterase 5"

showing 10 items of 11 documents

Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia

2018

javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe pulmonary complications as pulmonary hypertension. Because nitric oxide (NO) is a critical mediator in the development of pulmonary hypertension, the modulators of its downstream function may become target of pharmacological interventions aimed at alleviating the impact of this condition. Here, we investigate the effects of an early administration of phosphodiesterase-5 inhibitor in rats where pulmonary artery hypertension was induced by chronic exposure to hypoxia. javax.xml.bind.JAXBElement@162dc677 Rats were divided into three groups: normoxic control, hypoxic with …

0301 basic medicinemedicine.medical_specialtynitrites and nitratesPhysiologySildenafilsildenafil030204 cardiovascular system & hematologyphosphodiesterase 5lcsh:PhysiologyNitric oxideendothelial NO synthase; nitric oxide; nitrites and nitrates; phosphodiesterase 5; pulmonary hypertension; pulmonary vascular remodeling; right heart failure; sildenafil03 medical and health scienceschemistry.chemical_compound0302 clinical medicinenitric oxidePhysiology (medical)medicine.arteryInternal medicinepulmonary hypertensionmedicineendothelial NO synthaseOriginal ResearchCardiopulmonary diseaseLunglcsh:QP1-981business.industryright heart failureHypoxia (medical)medicine.diseasePulmonary hypertension030104 developmental biologymedicine.anatomical_structurechemistryVentriclePulmonary arteryCardiologymedicine.symptombusinesspulmonary vascular remodelingFrontiers in Physiology
researchProduct

Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors.

2011

Reliable and effective virtual high-throughput screening (vHTS) methods are desperately needed to minimize the expenses involved in drug discovery projects. Here, we present an improvement to the negative image-based (NIB) screening: the shape, the electrostatics, and the solvation state of the target protein’s ligand-binding site are included into the vHTS. Additionally, the initial vHTS results are postprocessed with molecular mechanics/generalized Born surface area (MMGBSA) calculations to estimate the favorability of ligand-protein interactions. The results show that docking produces very good early enrichment for phosphodiesterase-5 (PDE-5); however, in general, the NIB and the ligand-…

Cyclic Nucleotide Phosphodiesterases Type 5Virtual screeningHigh-Throughput Screening MethodsDrug discoveryChemistryGeneral Chemical EngineeringHigh-throughput screeningMedical screeningStatic ElectricityDrug Evaluation PreclinicalNanotechnologyGeneral ChemistryComputational biologyLibrary and Information SciencesMolecular Dynamics SimulationPhosphodiesterase 5 InhibitorsLigandsComputer Science ApplicationsHigh-Throughput Screening AssaysSubstrate SpecificityUser-Computer InterfaceDocking (molecular)Catalytic DomainJournal of chemical information and modeling
researchProduct

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

2017

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. Materials and methods Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record …

MaleAnoxemiaPulmonologyPulmonary FibrosisVasodilator Agentslcsh:MedicineVasodilation030204 cardiovascular system & hematologyPharmacologyVascular Medicinechemistry.chemical_compound0302 clinical medicineSoluble Guanylyl CyclaseHypoxic pulmonary vasoconstrictionPulmonary fibrosisMedicine and Health SciencesPulmonary Arterieslcsh:ScienceHypoxiaMultidisciplinaryVasodilatorsDrugsRespiratory organs diseasesArteriesMiddle AgedChemistryPhysical Sciencescardiovascular systemFemalemedicine.symptomAnatomyMedicamentsmedicine.drugResearch ArticleChemical Elementsinorganic chemicalsSildenafilHypertension PulmonaryChronic Obstructive Pulmonary DiseaseEnzyme ActivatorsIn Vitro TechniquesPulmonary ArteryRiociguatSildenafil CitrateMalalties de l'aparell respiratori03 medical and health sciencesMedical HypoxiamedicineVentilation-Perfusion RatioAnimalsHumansRats WistarAgedPharmacologybusiness.industrylcsh:RAnoxèmiaBiology and Life SciencesHypoxia (medical)Phosphodiesterase 5 Inhibitorsmedicine.diseasePulmonary hypertensionFibrosisRatsOxygenDisease Models AnimalPyrimidines030228 respiratory systemchemistryVasoconstrictionCardiovascular AnatomyPyrazolesBlood Vesselslcsh:QSoluble guanylyl cyclasebusinessDevelopmental Biology
researchProduct

Role of K+ and Ca2+ fluxes in the cerebroarterial vasoactive effects of sildenafil

2007

The aim of this study was to assess the role of K(+) and Ca(2+) fluxes in the cerebroarterial vasoactive effects of the phosphodiesterase-5 inhibitor sildenafil. We used isolated rabbit basilar arteries to assess the effects of extracellular K(+) raising on sildenafil-induced vasodilatation, and studied the pharmacological interaction of sildenafil with selective modulators of membrane K(+) and Ca(2+) channels. Expression of Kv1 subunits of K(+) channels was assessed at messenger and protein levels. Parallel experiments were carried out with zaprinast for comparison. Sildenafil (10 nM-0.1 mM) induced concentration-dependent relaxation of endothelin-1 (10 nM)-precontracted arteries, which wa…

Malemedicine.medical_specialtyCalcium Channels L-Typemedicine.drug_mechanism_of_actionPhosphodiesterase InhibitorsVasodilationIn Vitro TechniquesPharmacologyPiperazinesSildenafil Citratechemistry.chemical_compoundInternal medicinemedicineAnimalsChannel blockerRNA MessengerSulfonesPharmacologyTetraethylammoniumDose-Response Relationship DrugChemistryDepolarization3-Pyridinecarboxylic acid 14-dihydro-26-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)- Methyl esterIberiotoxinEndocrinologyPurinesBasilar ArterycGMP-specific phosphodiesterase type 5PotassiumShaker Superfamily of Potassium ChannelsCalciumRabbitsZaprinastPhosphodiesterase 5 inhibitorEuropean Journal of Pharmacology
researchProduct

Stroke after tadalafil use

2013

No abstract available

Malemedicine.medical_specialtyNeurologyStroke; tadalafil Phosphodiesterase inhibitorsDermatologyTadalafilInternal medicinemedicineHumansStrokeNeuroradiologymedicine.diagnostic_testCerebral infarctionbusiness.industrySettore MED/44 - Medicina Del LavoroBrainMagnetic resonance imagingGeneral MedicineMiddle AgedPhosphodiesterase 5 Inhibitorsmedicine.diseaseMagnetic Resonance ImagingTadalafilStrokePsychiatry and Mental healthSexual Dysfunction PhysiologicalSexual dysfunctionCardiologyNeurology (clinical)Neurosurgerymedicine.symptombusinesstadalafil Phosphodiesterase inhibitorsmedicine.drugCarbolines
researchProduct

Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single‐centre open‐label uncontrolled trial

2020

Phosphodiesterase-5 inhibitors are the first-line therapy for erectile dysfunction (ED) after radical prostatectomy (RP). This single-centre open-label uncontrolled study evaluated the efficacy and safety of the new sildenafil orodispersible film (ODF) in ED treatment after RP. Sildenafil 100 mg ODF was administered twice a week for 3 months to patients under 75 years of age, with a Framingham cardiovascular risk score < 20% and a pre-operative International Index of Erectile Function (IIEF)-5 score ≥ 17, who had undergone open RP between 2016 and 2018. Erectile function was assessed pre-operatively, post-operatively and after treatment through the IIEF-5 score, the Sexual Encounter Prof…

Malemedicine.medical_specialtyPercentileSildenafilUrologymedicine.medical_treatment030232 urology & nephrologyUrologyUncontrolled Studyprostatic neoplasmsSildenafil Citrate03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyErectile DysfunctiontherapeuticsHumansMedicineAdverse effectProstatectomy030219 obstetrics & reproductive medicineFramingham Risk Scorebusiness.industryProstatectomyPenile ErectionOrodispersible filmGeneral MedicinePhosphodiesterase 5 Inhibitorsmedicine.diseaseTreatment OutcomeErectile dysfunctionchemistrybusinessAndrologia
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells

2015

Current treatments for pulmonary arterial hypertension (PAH) include pulmonary vasodilators which may also inhibit PASMC proliferation. The aim of this study was to compare the antiproliferative effects of multiple drugs on rat and human PASMC (rPASMC and hPMASC, respectively) in vitro. rPASMCs and hPASMC were starved for 24 h, then treated with different inhibitors and incubated for 48 h in 1% foetal calf serum plus endothelin-1, 5-HT and U46619. Cell number was estimated by the MTT test. Viable cells increased by 160-180% in 48 h. Activation of the cGMP pathway with the soluble guanylyl cyclase activators riociguat and YC-1 (≤ 10 µM) or the cAMP pathway by the adenylyl cyclase activator f…

medicine.medical_specialtyForskolinmedicine.drug_mechanism_of_actionbusiness.industryProstacyclinPharmacologyRiociguatchemistry.chemical_compoundEndocrinologychemistryRho kinase inhibitorInternal medicinemedicinecAMP-dependent pathwayPotassium channel openerSoluble guanylyl cyclasebusinessPhosphodiesterase 5 inhibitormedicine.drug4.3 Pulmonary Circulation and Pulmonary Vascular Disease
researchProduct

Haemodynamic effects of long-term administration of sildenafil in normotensive pregnant and non-pregnant rats

2011

Please cite this paper as: Pellicer B, Herraiz S, Cauli O, Rodrigo R, Asensi M, Cortijo J, Serra V, Morcillo E, Felipo V, Simon C, Pellicer A. Haemodynamic effects of long-term administration of sildenafil in normotensive pregnant and non-pregnant rats. BJOG 2011;118:615–623. Objective  To determine the effects of chronic administration of sildenafil citrateon healthy pregnant rats. Design In vivo animal experimental study. Setting  Fundacion IVI–Instituto Universitario IVI, Valencia, Spain. Sample  Pregnant and non-pregnant Wistarrats exposed to chronic administration of sildenafil. Methods  Placental cross-barrier and feto-maternal relationship levels, maternal blood pressure, and haemody…

medicine.medical_specialtyPregnancyFetusmedicine.drug_mechanism_of_actionSildenafilbusiness.industryBlood viscosityObstetrics and Gynecologymedicine.diseasechemistry.chemical_compoundEndocrinologymedicine.anatomical_structurechemistryInternal medicinecardiovascular systemmedicineVascular resistanceGestationbusinessPhosphodiesterase 5 inhibitorDuctus venosusBJOG: An International Journal of Obstetrics & Gynaecology
researchProduct

PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION

2004

Abstract: Purpose: We established the efficacy and safety of sublingual apomorphine compared with oral sildenafil. in comparable groups of patients with erectile dysfunction (ED). Materials and Methods: This prospective, randomized, crossover study included 77 heterosexual men with ED of various etiologies and severities. A total of 62 men were randomized but only 34 were evaluable for efficacy and tolerability. The study started with a run-in period of 2 to 4 weeks. The first 4 weeks of treatment were followed by a washout period of 4 weeks, after which patients changed to the alternate treatment for an additional 4-week period. The sequence of the 2 treatments was established by a randomi…

medicine.medical_specialtyRandomizationmedicine.drug_mechanism_of_actionSildenafilUrologyUrologyPenis Impotence Apomorphine SildenafilSildenafil 50 MGlaw.inventionSettore MED/24 - Urologiachemistry.chemical_compoundRandomized controlled triallawmedicineProspective cohort studybusiness.industryMale erectile dysfunctionmedicine.diseaseCrossover studyrespiratory tract diseasesApomorphineErectile dysfunctionmedicine.anatomical_structureTolerabilitychemistryAnesthesiacardiovascular systemSexual functionbusinessPhosphodiesterase 5 inhibitorPenismedicine.drug
researchProduct